Results

Pfizer Inc.

09/17/2021 | Press release | Distributed by Public on 09/17/2021 16:08

Astellas’ and Pfizer’s XTANDI® (enzalutamide) Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES Study